Furthermore, silencing CBL-c expression sensitized the NSCLC cells with EGFR mutations to the treatment with tyrosine kinase inhibitors, thus enhancing their therapeutic effectiveness. The gene discussed is CBLC; the disease is non-small cell lung carcinoma.